Search research articles
Contact Us
Filters
Showing results (21-30 of 59) with videos related to
Page
of 6
Sort By:
International Clinical Psychopharmacology
|
July 15, 2025
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study
Mauricio Tohen, Suresh Durgam, Susan G Kozauer, et al.
Depression and Anxiety
|
April 21, 2015
A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder
Carl Gommoll, Suresh Durgam, Maju Mathews, et al.
The Journal of Clinical Psychiatry
|
May 28, 2016
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial
Suresh Durgam, Carl Gommoll, Giovanna Forero, et al.
Neuropsychiatric Disease and Treatment
|
June 25, 2026
Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial
Michael E Thase, Willie R Earley, Susan G Kozauer, et al.
Journal of Affective Disorders
|
October 11, 2017
Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder
Willie Earley, Suresh Durgam, Kaifeng Lu, et al.
Journal of Affective Disorders
|
March 27, 2017
Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies
Willie Earley, Suresh Durgam, Kaifeng Lu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 25, 2026
Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study
Suresh Durgam, Willie R Earley, Susan G Kozauer, et al.
International Journal of Clinical Practice
|
November 10, 2017
Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
Suresh Durgam, Willie Earley, Kaifeng Lu, et al.
CNS Drugs
|
July 15, 2026
Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials
Willie R Earley, Suresh Durgam, Susan G Kozauer, et al.
International Clinical Psychopharmacology
|
July 26, 2018
Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
Suresh Durgam, Carl Gommoll, Raffaele Migliore, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 59) with videos related to
Sort By:
Page
of 6
International Clinical Psychopharmacology
|
July 15, 2025
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study
Mauricio Tohen, Suresh Durgam, Susan G Kozauer, et al.
Depression and Anxiety
|
April 21, 2015
A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder
Carl Gommoll, Suresh Durgam, Maju Mathews, et al.
The Journal of Clinical Psychiatry
|
May 28, 2016
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial
Suresh Durgam, Carl Gommoll, Giovanna Forero, et al.
Neuropsychiatric Disease and Treatment
|
June 25, 2026
Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial
Michael E Thase, Willie R Earley, Susan G Kozauer, et al.
Journal of Affective Disorders
|
October 11, 2017
Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder
Willie Earley, Suresh Durgam, Kaifeng Lu, et al.
Journal of Affective Disorders
|
March 27, 2017
Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies
Willie Earley, Suresh Durgam, Kaifeng Lu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 25, 2026
Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study
Suresh Durgam, Willie R Earley, Susan G Kozauer, et al.
International Journal of Clinical Practice
|
November 10, 2017
Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
Suresh Durgam, Willie Earley, Kaifeng Lu, et al.
CNS Drugs
|
July 15, 2026
Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials
Willie R Earley, Suresh Durgam, Susan G Kozauer, et al.
International Clinical Psychopharmacology
|
July 26, 2018
Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
Suresh Durgam, Carl Gommoll, Raffaele Migliore, et al.
Page
of 6